Inspire Medical Systems, Inc. (INSP) Guidance & Earnings Results

On 2026-08-03 Inspire Medical Systems, Inc. raised guidance: "FY2026 revenue raised to $835-875M from prior range; FY2026 adjusted operating margin 4-6%; FY2026 diluted EPS $(0.42)-$0.17; FY2026 adjusted diluted EPS $1.05-$1.45; FY2026 capex $35-40M; FY2026 effective tax rate…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

INSPInspire Medical Systems, Inc.Follow INSP — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 2.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 2 Nov, in 9 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
3 Aug 26	Raised	FY2026 revenue raised to $835-875M from prior range; FY2026 adjusted operating margin 4-6%; FY2026 diluted EPS $(0.42)-$0.17; FY2026 adjusted diluted EPS $1.05-$1.45; FY2026 capex $35-40M; FY2026 effective tax rate 95-100%; FY2026 adjusted effective tax rate 30-35% · full year
12 Jan 26	Raised	FY2026 revenue guidance $1,003M-$1,013M, 10-11% growth
3 Nov 25	Raised	FY2025 diluted EPS guidance raised from $0.40-$0.50 to $0.90-$1.00 · full year
4 Aug 25	Lowered	FY2025 revenue $900-910M (prior $940-955M); diluted EPS $0.40-0.50 (prior $2.20-2.30); gross margin maintained 84-86% · full year

Inspire Medical Systems, Inc. — questions

What guidance did Inspire Medical Systems, Inc. give?: On 2026-08-03: "FY2026 revenue raised to $835-875M from prior range; FY2026 adjusted operating margin 4-6%; FY2026 diluted EPS $(0.42)-$0.17; FY2026 adjusted diluted EPS $1.05-$1.45; FY2026 capex $35-40M; FY2026 effective tax rate 95-100%; FY2026 adjusted effective tax rate 30-35%"
When does Inspire Medical Systems, Inc. report earnings?: Inspire Medical Systems, Inc.'s next earnings report is expected on 2026-11-02.

Every figure on this page comes from Inspire Medical Systems, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.